Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (MRNS)
NASDAQ:MRNS
Holding MRNS?
Track your performance easily
MRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.26 - $11.26
Previous Close$0.31
Volume661.41K
Average Volume (3M)2.48M
Market Cap
$16.97M
Enterprise Value$29.96M
Total Cash (Recent Filing)$42.20M
Total Debt (Recent Filing)$55.19M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Mar 11, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding55,185,622
10 Day Avg. Volume1,320,037
30 Day Avg. Volume2,484,477
Standard Deviation0.28
R-Squared0.05
Alpha-0.00444
Financial Highlights & Ratios
Price to Book (P/B)-0.26
Price to Sales (P/S)0.54
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit1.03
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$1.76Price Target Upside469.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Marinus News
Bulls Say, Bears Say
Bulls Say
Clinical Development And Trial OptimizationConfident in positive results from the Phase 3 TRUST-TSC trial based on learnings from CDD, positive Phase 2 TSC results, and Phase 3 trial design optimization.
Commercial OpportunitiesThere is potential for a partner or acquirer for ZTALMY given its established launch success in patients with CDKL5-deficiency disorder.
Drug Approval And Market PotentialZtalmy (oral ganaxolone) is the only drug approved for seizures associated with CDKL5 deficiency disorder in several countries.
Bears Say
Clinical Trial OutcomesThe Phase 3 TRUST-TSC trial failed to meet its primary endpoint, demonstrating a numerical but not statistically significant reduction in seizure frequency vs. placebo.
Financial PerformanceThe stock is trading down more than 70% and at a significant discount to cash, reflecting uncertainties similar to other biotech companies.
Strategic DecisionsThe company is discontinuing further development of ganaxolone and implementing cost reduction measures including a reduction in workforce.
---
Ownership Overview
1.34% Insiders
9.79% Mutual Funds
40.85% Other Institutional Investors
42.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNS FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $0.26 and its highest was $11.26 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Mar 11, 2025 which is in 110 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Nov 12, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.409 by -$0.011.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.29.
How many shares outstanding does Marinus have?
Marinus has 55,185,623 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.409. Following the earnings report the stock price went down -11.765%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is Woodline Partners LP. It holds Marinus’s shares valued at 7M.
---
Marinus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.76 (469.58% Upside)
$1.76 (469.58% Upside)
Blogger Sentiment
Bullish
MRNS Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 84.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.32%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Earnings Call
Q2 2024
0:00 / 0:00
---
MRNS Stock 12 Month Forecast
Average Price Target
$1.76
▲(469.58% Upside)
Technical Analysis
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-24.19%
reiterated a buy rating 2 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -24.19% per trade.
---